News
Hengrui gets world-first okay for platelet drug hetrombopag
Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.
Sales & Marketing
Pharma's engagement problem: Are we expecting too much from ...
The question is no longer simply how to attract healthcare professionals to an event. The bigger challenge is how to create meaningful engagement.
News
Reviews underway of first drug for rare disease MOGAD
Patients with rare autoimmune disease MOGAD could be months away from having a first approved therapy, as the FDA starts a review of Roche's Enspryng.
News
Bayer moves Hyrnuo into frontline lung cancer treatment
Bayer chases after Boehringer with an FDA approval for oral HER2 inhibitor Hyrnuo in previously untreated HER2+ lung cancer.
News
FDA starts review of AZ's COPD blockbuster hope
The FDA has started a priority review of AstraZeneca's first-in-class IL-33 inhibitor tozorakimab for COPD, setting up a decision in Q1 of 2027.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
